You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海正藥業(600267.SH):擬合資設立合成生物學獨立子公司

格隆匯6月19日丨海正藥業(600267.SH)公佈,爲進一步優化管理體系、提升決策效率,同意公司與全資子公司瀚暉製藥有限公司之香港全資子公司輝正國際有限公司(簡稱“輝正國際”)合資設立合成生物學獨立子公司,實現資源整合和集中管理,結合輝正國際在香港的平臺優勢,爲公司合成生物學業務的專業化、規模化發展提供有力支撐。海正藥業擬認繳出資額爲2.6億元人民幣,佔註冊資本的74.29%,根據萬邦資產評估有限公司出具的《浙江海正藥業股份有限公司擬實物資產出資涉及的單項資產市場價值評估項目資產評估報告》(萬邦評報〔2025〕245號),本次評估涉及的單項資產在資產評估基準日2025年5月31日的市場價值(不含增值稅)爲243,782,624.49元,公司以實物資產的含稅價值作爲認繳出資額,不足部分以現金補足。輝正國際擬認繳出資額爲0.9億元人民幣(或等值外幣),佔註冊資本的25.71%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account